Opinion|Videos|July 5, 2023
Achieving Durable Clinical Response with Targeted Treatment for Vitiligo
In this MEDcast episode, Dr Chovatiya and Dr Bunick delve into the advancements in targeted treatments for vitiligo, exploring their potential to provide long-term efficacy and durable clinical response.
Advertisement
Episodes in this series
0:53 Quality of life impact of vitiligo
2:55 Pathogenesis of vitiligo
5:08 Approaches to vitiligo treatment
8:30 Mechanism of JAK inhibitors
10:25 TRuE-V1 and TRuE-V2 studies for the JAK inhibitor ruxolitinib
14:15 Variation in repigmentation with vitiligo
17:20 Safety of topical ruxolitinib
21:00 Data from the long-term extension trial of ruxolitinib
25:75 Achieving meaningful treatment response in vitiligo
30:15 Investigational biomarkers and treatments for vitiligo
Advertisement
Related to this article
Experts discuss remibrutinib, the first FDA-approved therapy for symptomatic dermographism: RemIND data, bleeding counseling, and where it fits in practice
Lindsay Ackerman, MD, and Chris Bunick, MD, PhD, examine how ORAL Surveillance shaped JAK warnings and what long-term atopic dermatitis data show.
Lindsay Ackerman, MD, and Chris Bunick, MD, PhD, discuss where topical PDE4 inhibitors fit in atopic dermatitis and how to measure skin and itch response.
Shannon C. Trotter, DO, and Mona Shahriari, MD, discuss burnout, people-pleasing, public speaking, and the real life behind physicians’ polished personas.
This segment of Nguyen's 2026 Fall Clinical Dermatology interview highlights key insights on early dermatology career strategies and other information.
Alia Galadari, MD, discusses subtle erythema, commonly missed diagnoses, and research gaps to help clinicians recalibrate their approach to skin of color.
Stay updated with the latest healthcare breakthroughs, including Otsuka’s sibeprenlimab 24-month eGFR data in IgA nephropathy.
Advertisement
Advertisement
Trending on HCPLive
1
Cardiac Health Indicators Improve Following CCM Implantation in Heart Failure
2
Sarcoidosis Care Starts With Inflammation vs Fibrosis: Rohit Gupta, MD
3
ASN Kidney Week 2026 Recap: 8 Key Updates in Kidney Disease to Know
4
HCPLive Five at CHEST 2026
5